(Q44007986)

28 November 2017

Clusterin inhibition to enhance tumor chemosensitivity in systemic tumors (English)

1 reference

28 November 2017

Shailendra Kapoor

1

1 reference

28 November 2017

6 February 2013

1 reference

Cancer Chemotherapy and Pharmacology

28 November 2017

1 reference

28 November 2017

71

1 reference

28 November 2017

4

1 reference

28 November 2017

1101

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-013-2072-6

28 November 2017

0 references

cites work

Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2072-6

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2072-6

Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2072-6

Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2072-6

Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2072-6

10.1007/S00280-013-2072-6

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference

PubMed ID

23385781